465 related articles for article (PubMed ID: 27090956)
1. Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.
Kang HJ; Hong KT; Lee JW; Kim H; Park KD; Shin HY; Lee SH; Yoo KH; Sung KW; Koo HH; Lee JW; Chung NG; Cho B; Kim HK; Koh KN; Im HJ; Seo JJ; Jung HJ; Park JE; Lee YH; Lim YT; Lim YJ; Kim SY; Yoo ES; Ryu KH; Lee JH; Park JA; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1455-1459. PubMed ID: 27090956
[TBL] [Abstract][Full Text] [Related]
2. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.
Kang HJ; Shin HY; Choi HS; Ahn HS
Bone Marrow Transplant; 2004 Dec; 34(11):939-43. PubMed ID: 15489866
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
Kim H; Lee KH; Kim I; Sohn SK; Jung CW; Joo YD; Kim SH; Kim BS; Choi JH; Kwak JY; Kim MK; Bae SH; Shin HJ; Won JH; Lee WS; Oh S; Kim HJ; Park JH;
Leuk Res; 2014 Jul; 38(7):730-6. PubMed ID: 24840870
[TBL] [Abstract][Full Text] [Related]
8. Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia.
Chung NG; Lee JW; Jang PS; Jeong DC; Cho B; Kim HK
Pediatr Transplant; 2013 Jun; 17(4):387-93. PubMed ID: 23551397
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
Bacigalupo A; Locatelli F; Lanino E; Marsh J; Socié G; Maury S; Prete A; Locasciulli A; Cesaro S; Passweg J;
Bone Marrow Transplant; 2005 Dec; 36(11):947-50. PubMed ID: 16205733
[TBL] [Abstract][Full Text] [Related]
10. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
[TBL] [Abstract][Full Text] [Related]
11. Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
Mori T; Koh H; Onishi Y; Kako S; Onizuka M; Kanamori H; Ozawa Y; Kato C; Iida H; Suzuki R; Ichinohe T; Kanda Y; Maeda T; Nakao S; Yamazaki H
Int J Hematol; 2016 Apr; 103(4):461-8. PubMed ID: 26910242
[TBL] [Abstract][Full Text] [Related]
12. A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia.
Ommati LV; Rodrigues CA; Silva AR; Silva LP; Chaufaille ML; Oliveira JS
Braz J Med Biol Res; 2009 Mar; 42(3):244-50. PubMed ID: 19287903
[TBL] [Abstract][Full Text] [Related]
13. Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.
Shin SH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Lee JW
Bone Marrow Transplant; 2016 Nov; 51(11):1456-1463. PubMed ID: 27348538
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
Maury S; Bacigalupo A; Anderlini P; Aljurf M; Marsh J; Socié G; Oneto R; Passweg JR;
Haematologica; 2009 Sep; 94(9):1312-5. PubMed ID: 19734425
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
Takpradit C; Prockop SE; Kernan NA; Scaradavou A; Curran K; Ruggiero J; Zakak N; O'Reilly RJ; Boulad F
J Pediatr Hematol Oncol; 2018 May; 40(4):e220-e224. PubMed ID: 29432302
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Ghanem KM; Kharfan-Dabaja MA; El-Solh H; Harris N; Kreidieh N; Nehme R; Muwakkit SA; Saab R; Bazarbachi A; Abboud MR
Curr Res Transl Med; 2017 Sep; 65(3):115-119. PubMed ID: 28988743
[TBL] [Abstract][Full Text] [Related]
17. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
18. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
Horan JT; Haight A; Dioguardi JL; Brown C; Grizzle A; Shelman C; Kanter J; Hale G; Nieder M; Benton M; Kasow KA; Abraham A; Chiang KY
Biol Blood Marrow Transplant; 2015 May; 21(5):900-5. PubMed ID: 25617808
[TBL] [Abstract][Full Text] [Related]
19. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
20. Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.
Lee SE; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW
Am J Hematol; 2018 Nov; 93(11):1368-1375. PubMed ID: 30117176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
